Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ArQule Signs c-Met Inhibitor, Discovery Platform Deals With Daiichi-Sankyo

This article was originally published in The Pink Sheet Daily

Executive Summary

Two deals bring the biotech $75 million upfront, plus research and clinical development funding.

You may also be interested in...



Deals Of The Week: Will Heated Competition To Buy Out Ache Laboratorios Muddy The Brazilian Waters?

Pfizer, Novartis and Abbott reportedly are battling to buy out family-owned Ache, Brazil’s leader in prescription drug sales. Plus deals involving AstraZeneca and AlphaCore, Pfizer and Bind Therapeutics and Merck and Ra Pharma.

ArQule Gets Early-Stage Cancer Program Back From Daiichi

The Japanese pharma has elected to return rights to an early-stage cancer development program to ArQule, but the biotech reassured investors the two companies will continue to move forward on their beleaguered late-stage oncology endeavor.

ArQule Pleads Tivantinib’s Promise In Liver Cancer After Lung Cancer Blow-up

Progression-free survival benefit fails to translate into overall survival in Phase III NSCLC study of c-Met inhibitor tivantinib, partnered with Daiichi Sankyo. ArQule shifts focus to an imminent, targeted second-line Phase III study of high-Met expressing hepatocellular cancer.

Related Content

Topics

UsernamePublicRestriction

Register

PS067009

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel